Effects of endothelin-1 on components of anterograde axonal transport in optic nerve.
OBJECTIVE
Increased levels of endothelins (ETs) are associated with glaucoma and have been said to contribute to the development of glaucomatous optic neuropathy. In glaucoma, movement of selected components of anterograde axonal transport essential in ganglion cell survival is impaired-specifically, the transport of mitochondria. This study evaluates the effect(s) of a single administration of intravitreous ET-1 on anterograde axonal transport in the rat optic nerve.


METHODS
Proteins for anterograde axonal transport were pulse labeled by intravitreous injection of (35)S-methionine plus or minus ET-1 (2 nmol) in HEPES buffer (pH 7.4). At appropriate time intervals, optic nerves were dissected, sectioned while frozen, and homogenized in denaturing buffer, and transported protein was quantitated by liquid scintillation counting. Counts corrected for efficiency, quench, background, and decay were statistically evaluated (ANOVA, n = 7).


RESULTS
Effects of treatment with intravitreous ET-1 on anterograde axonal transport were significant, biphasic, and prolonged (4 hours to 21 days). The initial phase was a significant enhancement of transport at times normally associated with small, fast-moving tubulovesicles (4 and 24 hours), followed by significant impairments at times normally associated with transport of mitochondria (28-36 hours), cytoplasmic matrix (4 days), and cytoskeletal proteins (21 days). The most pronounced effect of ET-1 was decreased axonal transport at times associated with normal anterograde transport of mitochondrial proteins (28, 32, and 36 hours, P = < 0.001, P < 0.015, and P < 0.001, respectively). This was mimicked by ET-3 at 28 hours.


CONCLUSIONS
Effects of intravitreous ET-1 are consistent with a receptor-mediated role for elevated ETs in pathologic misregulation(s) of anterograde axonal transport.
D000818:Animals; D001370:Axonal Transport / Q000187:drug effects*; D001693:Biological Transport, Active / Q000187:drug effects; D019332:Endothelin-1 / Q000008:administration & dosage / Q000494:pharmacology*; D019334:Endothelin-3 / Q000494:pharmacology; D008297:Male; D008928:Mitochondria / Q000378:metabolism; D009900:Optic Nerve / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014822:Vitreous Body / Q000502:physiology
D019332:Endothelin-1; D019334:Endothelin-3
Non-programmatic